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PHARMACODYNAMICS AND 
DRUG ACTION 
Hemodynamic effects of quinapril, a novel 
angiotensin- converting enzyme inhibitor 
The hemodynamic effects of quinapril, a novel nonsulfhydryl-containing angiotensin-converting enzyme 
(ACE) inhibitor, were assessed in 10 patients with mild-to-moderate essential hypertension. Compared 
with placebo, quinapril (20 mg) administered twice daily for 4 weeks significantly lowered blood pressure 
by decreasing total peripheral resistance without producing tachycardia, an increase in cardiac output, or 
a rise in plasma catecholamines. Quinapril significantly reduced renal, but not forearm, vascular resistance. 
Renal blood flow, glomerular filtration rate, and filtration fraction remained unchanged. Left ventricular 
wall stress was markedly reduced by quinapril, but during the relatively short treatment period, only a 
nonsignificant trend toward reduction in left ventricular mass was observed. These findings suggest that 
quinapril is an effective antihypertensive agent that lowers peripheral resistance without increasing car- 
diac output or disturbing autoregulation of renal hemodynamics. (CLIN PHARMACOL THER 1990;48: 
41-9.) 
Rakesh K. Gupta, MD, Sverre E. Kjeldsen, MD, Lisa Krause, MS, Jill Kneisley, MS, 
Edward Posvar, MD, Alan B. Weder, MD, and Stevo Julius, MD Ann Arbor, Mich. 
The hemodynamic hallmark of untreated essential 
hypertension is increased vascular resistance in most 
vascular beds.' Even in relatively young patients (20 
to 40 years of age) with mild hypertension, in whom 
the typical hemodynamic pattern is an increased cardiac 
index during rest with almost normal total peripheral 
resistance, exercise fails to lower total peripheral re- 
sistance as much as it does in normotensive age- 
matched control subjects. In addition, subnormal stroke 
index and cardiac index can be demonstrated in such 
patients during exercise.' When hypertension is left un- 
treated, the hemodynamic pattern changes over time, 
evolving toward a "low cardiac outputhigh resistance" 
pattern with reduced left ventricular compliance and 
left ventricular hypertrophy in a large fraction of the 
patients.' These are the changes we would like to pre- 
vent or reverse with antihypertensive treatment. 
Currently available antihypertensive drugs lower 
blood pressure through widely different hemodynamic 
mechanisms. In general, P-adrenoreceptor blockers 
From the University of Michigan, Department of Internal Medicine, 
Division of Hypertension, and Parke-Davis Pharmaceutical Re- 
search Division, Warner-Lambert Co. 
Received for publication Aug. 17, 1989; accepted Dec. 5, 1989. 
Reprint requests: Svene E. Kjeldsen, MD, Department of Internal 
Medicine, Ullevaal Hospital, N-0407 Oslo 4, Norway. 
13/1/18608 
tend to result in a chronic depression in cardiac output, 
particularly during exercise,' and may lead to less phys- 
ical endurance during severe work loads.5' In contrast, 
a-adrenoreceptor blockers, calcium channel blockers, 
and angiotensin-converting enzyme (ACE) inhibitors 
reduce vascular resistance and maintain blood flow,8-'4 
but the degree of counteracting reflex tachycardia and 
increase in cardiac output varies widely. 
It is likely that the blood pressure lowering effect of 
ACE inhibitors is mediated largely by withdrawal of 
the vasopressor influences of angiotensin 11,1516 al- 
though other mechanisms such as bradykinin potentia- 
tion may participate. Both angiotensin II withdrawal 
and bradykinin increase would result in dilation of the 
arteriolar resistance vessels. Quinapril hydrochloride 
(C1-906) is a new potent, orally active, nonsulfhydryl, 
nonpeptide ACE inhibitor developed for the treatment 
of hypertension and congestive heart failure. Quinapril 
is converted in vivo to its active metabolite, quinaprilat, 
which is primarily responsible for its potent ACE in- 
hibition. Clinical studies indicate that quinapril is an 
effective antihypertensive agent when administered 
once or twice daily. The acute hemodynamic effects 
of quinapril have been studied in patients with conges- 
tive cardiac failure.' However, there is little informa- 
tion on the chronic hemodynamic effects of quinapril 
in patients with hypertension. Therefore, the aim of the 
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present study was to compare the hemodynamic effects 
of quinapril with placebo during long-term (4 weeks) 
treatment of patients with mild-to-moderate essential 
hypertension in a double-blind, randomized crossover 
design. 
MATERIAL AND METHODS 
Patients. Ten white men averaging 42 ± 3 years of 
age (range, 32 to 61 years) with uncomplicated mild- 
to-moderate essential hypertension were studied. Initial 
body weight averaged 83 ± 5 kg, and height averaged 
166 ± 5 cm. After informed consent was obtained 
from the subjects, all antihypertensive medications 
were discontinued for 3 weeks, and patients were in- 
cluded if they had stable diastolic blood pressure be- 
tween 95 and 115 mm Hg at home (sitting) and in the 
outpatient clinic (supine) at the end of this period. Av- 
erage values for their sitting blood pressure in the out- 
patient clinic at this time were 149 ± 4 mm Hg for 
systolic, 106 ± 2 mm Hg for diastolic and 120 ± 3 
mm Hg for mean blood pressure. Aside from essential 
hypertension, no subject had any other acute or chronic 
illness except for one patient who was receiving stable 
thyroid hormone replacement. Physical examination, 
ECG, urinalysis, blood counts, and blood biochemis- 
tries (including liver and renal function tests) were done 
to exclude any other concomitant illness or cause of 
secondary hypertension. The patients were all non- 
smokers and were known not to abuse alcohol or drugs. 
They were urged not to make any changes in their 
dietary, smoking, or alcohol consumption habits during 
the entire period of the study. 
Protocol. The study was approved by the Human 
Subject Review Committee of the University of Mich- 
igan (Ann Arbor, Mich.). After an initial 3-week wash- 
out period without antihypertensive treatment, the pa- 
tients were randomized to a double-blind, two-period 
crossover trial comparing quinapril and placebo. Qui- 
napril 20 mg twice a day or matching placebo twice a 
day (both provided by Warner Lambert/Parke-Davis, 
Ann Arbor, Mich.) were each given for 4 weeks. Ad- 
herence to the study protocol was monitored by having 
the patients keep a diary and by tablet counting by the 
investigators. For safety reasons potential side effects 
or adverse reactions were monitored by asking the pa- 
tients to make notes in the diary, by direct questioning 
by the investigator, and by drawing blood for routine 
chemistry including liver enzymes before and after 1 
and 4 weeks in both treatment periods. On the last day 
of each 4-week period, patients were admitted to the 
University of Michigan Clinical Research Center for 4 
hours. They were instructed not to take over-the-counter 
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medications except acetaminophen for at least 10 days. 
Only one patient was studied each day beginning at 
8 AM, and all studies were performed by the same 
physicians. 
After an overnight fast, that is, 12 hours after taking 
the last PM dose of the medication, subjects were placed 
at supine rest in a quiet room where temperature was 
strictly standardized to 75° F (23.9° C). They were 
allowed to watch television. A short teflon catheter was 
initially placed into an antecubital vein of the right arm 
of each subject and was kept open with a 10 ml per 
hour infusion of 0.9% sodium chloride. Blood pressure 
was measured in the right arm as the average of two 
readings by use of a newly calibrated mercury sphyg- 
momanometer, and heart rate was calculated from the 
average of 20 to 40 beats taken from the ECG. 
Forearm blood flow (FBF) was also measured as the 
average of two readings by mercury-in-Silastic strain 
gauge, venous occlusion plethysmography by use of the 
EC-4 plethysmograph and E-10 rapid cuff inflator (Hok- 
anson Instruments, Issaquah, Wash.). This technique 
has previously been described in detail and evaluated 
in our laboratory.2' The left arm was supported above 
heart level, and the strain gauge placed around the fore- 
arm, approximately 7 cm below the olecranon. Hand 
blood flow was arrested by a pediatric-sized cuff in- 
flated to suprasystolic pressure at the wrist 60 seconds 
before FBF determinations. A second cuff on the arm 
was subsequently inflated to 40 to 50 mm Hg for 10 to 
15 seconds and deflated for 5 seconds or more before 
the next measurement. Forearm blood flow (m1/100 ml 
forearm volume per minute) was calculated from the 
mean vertical deflection per minute on the tracings di- 
vided by the 1% electrical calibration signal. Forearm 
vascular resistance (FVR) was calculated as mean ar- 
terial blood pressure (MAP) determined during the pro- 
cedure divided by FBF. 
After measuring baseline blood pressure, heart rate, 
and FBF, the morning dose of medication (quinapril or 
placebo) was given with 100 ml water. Thereafter, 
blood pressure, heart rate, and FBF were measured 
every 1/2 hour throughout, and hemodynamic profiling 
was done 2 to 4 hours after the medication was ad- 
ministered. Clinical studies in patients with hyperten- 
sion have demonstrated that peak change in diastolic 
blood pressure following quinapril administration oc- 
curs at 2 to 4 hours after administration of the dose 
(Parke-Davis, data on file). Therefore this time frame 
was chosen to determine peak hemodynamic and blood 
pressure changes after quinapril administration. 
Cardiac output was measured 3 hours after dose 
administration by an echocardiographic Doppler 
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Table I. Blood pressure, heart rate, forearm blood flow, and forearm vascular resistance for subjects in the 
supine position for 4 hours after taking the study medication at 8 AM 
Data are mean values ± SE (n = 10). 
*p < 0.01; tp < 0.001; tp < 0.05 (quinapril versus placebo). 
technique utilizing an ATL Ultramark IV (Belle- 
vue, Wash.). This method has previously been vali- 
dated against dye dilution in our laboratory.' Two- 
dimensional images of the aortic root were recorded in 
the long-axis view by use of a 2.25 MHz transducer. 
The aortic root diameter was measured from the two- 
dimensional image at the level of the aortic leaflets 
during mid-systole and the aortic crosszsectional area 
was calculated. Aortic outflow measurements were ob- 
tained from the suprasternal notch with a continuous 
wave Doppler transmitter operating at 3.0 MHz. The 
cardiac output and stroke volume measurements were 
calculated by use of a computer-interfaced digitizing 
tablet and Doppler analysis program (Freeland Medical 
Systems, Indianapolis, Ind.). The average of eight con- 
secutive cardiac cycles was taken, and only those Dopp- 
ler recordings that showed maximal flow velocities and 
exhibited the "cleanest" envelopes were chosen. The 
flow velocity integral (FVI), or the area under the ve- 
locity curve was determined by tracing from the base- 
line around the maximal velocity curve. Heart rate was 
measured from the RR interval of the simultaneously 
recorded ECG. Stroke volume was calculated by use 
of the formula: 
SV (m1) = FVI (cm) x CSA (cm2) 
Cardiac output was calculated by multiplying 
stroke volume (SV) by heart rate. Cardiac index (CI, 
L/ min/ m2) was calculated as the ratio of cardiac output 
to body surface area estimated from height and weight 
in conventional tables. Total peripheral resistance index 
Hemodynamic effects of quinapril 43 
(103 dynes/cm') 
Data are mean values -± SE (n = 10). 
*p <0.01. 
(TPRI) was calculated as MAP/CI. Left ventricular 
mass (LVM) was calculated by use of the formula: 
LVM (gm) = 1.04 [(left ventricular internal diameter + 
left ventricular septal thickness + 
posterior wall thickness)3 - 
(left ventricular internal diameter)3] - 13.6 
Ejection fraction was determined by use of the formula: 
[LV internal diameter (diastole)]3 - [LV internal diameter 
(systole)]3/[LV internal diameter (diastole)]3 X 100 
Left ventricular mass and ejection fraction measure- 
ments were obtained from M-mode echocardiographic 
recordings. Left ventricular peak systolic wall stress 
was calculated as follows: 
1.332 x systolic BP X D/4 h (1 + h/D) 103 dynes/cm' 
Table II. Echocardiographic and Doppler 
measurements done with the subjects in the 
supine position 3 hours after dose 
administration to subjects receiving long-term 
treatment with quinapril and placebo 
Placebo Quinapril 
Cardiac output (L/min) 4.74 ± 0.25 4.78 ± 0.19 
Stroke volume (ml/min) 75.7 ± 4.2 74.9 ± 3.4 
Ejection fraction (%) 76.3 ± 2.6 73.6 ± 2.9 
Left ventricular mass (gm) 220 ± 19 210 ± 14 
Left ventricular wall stress 170 ± 8 149 ± 9* 
0 30 60 90 120 150 180 210 240 
Minutes Minutes Minutes Minutes Minutes Minutes Minutes Minutes Minutes 
Systolic blood pressure (mm Hg) 
Placebo 151 ± 6 149 ± 6 149 ± 5 148 ± 6 150 ± 6 151 ± 5 150 -± 5 151 ± 5 152 ± 5 
Quinapril 135 ± 5* 134 ± 51- 135 ± 6t 134 ± 5* 134 ± 6* 136 ± 6* 136 -± 5* 137 ± 6t 139 ± 5t 
Diastolic blood pressure (mm Hg) 
Placebo 102 ± 3 102 ± 3 103 ± 3 102 ± 3 104 ± 3 104 ± 3 105 ± 3 106 ± 3 106 ± 3 
Quinapril 93 ± 4* 94 -± 4* 95 -± 3t 94 ± 3* 95 ± 3t 94 ± 3t 94 ± 3t 96 ± 3* 98 ± 3* 
Heart rate (beats/min) 
Placebo 66 -± 3 65 -± 3 65 ± 3 64 ±3 65 ± 3 66 ± 3 66 ± 3 67 ± 3 70 ± 4 
Quinapril 66 J.: 3 65 ± 2 64 ± 3 63 ±2 63 ± 2 66±3 3 65 ± 2 68 ± 3 68 ± 3 
Forearm blood flow (m1/100 ml forearm volume/min) 
Placebo 2.9 ± 0.5 2.5 ± 0.4 2.8 ± 0.4 3.0 ± 0.5 3.2 ± 0.5 3.0 ± 0.5 3.0 ± 0.3 3.2 -± 0.6 3.1 ± 0.5 
Quinapril 2.8 ± 0.4 3.4 -± 0.9 3.4 ± 0.9 3.2 -± 0.6 2.9 ±- 0.4 3.2 -± 0.5 2.9 ± 0.4 3.1 ± 0.5 3.0 -± 0.4 
Forearm vascular resistance (arbitary units) 
Placebo 41 ± 6 47 ± 9 42 ± 7 39 ±9 37 ± 7 40 ± 12 40 ± 7 38 ± 11 39 ± 11 
Quinapril 38 ± 4 32 ± 6 32 ± 7 33 ±5 37 ± 5 34 ± 9 37 ± 5 35±5 5 37 ± 5 
in which D is the left ventricular diameter (diastole) 
and h is the [interventricular septum thickness (dias- 
tole) + LV posterior wall (diastole)] /2. All the echo- 
cardiographic and Doppler examinations were per- 
formed by the same technician. 
Plasma clearance of para-aminohippuric acid (PAH) 
was measured by a steady-state infusion method2324 as 
an estimate of effective renal plasma flow (RPF). PAH 
(20 mg / ml, MSD, West Point, Pa.) was mixed in 5% 
dextrose solution at a final concentration of 8 mg / ml, 
and 8 mg PAH per kilogram of body weight was given 
as a rapid infusion over 10 minutes followed by a sus- 
taining infusion for 1 hour, from 21/2 to 31/2 hours after 
giving the dose of quinapril or placebo. The sustaining 
infusion rate of PAH was calculated from the formula: 
Infusion rate of PAH = CL. X PPAH 
in which CLpAH is the estimated clearance of PAH (750 
ml/ min /1.73 m2), and Ppm/ is the target plasma PAH 
(0.02 mg /m1). 
Blood for analysis of plasma PAH was drawn im- 
mediately before giving PAH intravenously through the 
indwelling catheter in the right antecubital vein (plasma 
blank) and at the end of the 1 hour of intravenous 
infusion of PAH (steady-state level) by direct puncture 
of the left antecubital vein with a heparinized vacutai- 
ner. Plasma concentration of PAH was determined by 
colorimetric assay. PAH clearance was calculated as the 
ratio of infusion rate and difference in plasma concen- 
tration of PAH between the two blood samples. He- 
matocrit was obtained by use of a Coulter Counter 
M4 30 (Coulter Electronics, Inc., Hialeah, Fla.), and 
renal blood flow (RBF) was calculated as RPF/ 1 
hematocrit. Renal vascular resistance (RVR) was cal- 
culated as MAP / RBF. 
Endogenous creatinine clearance was measured to 
estimate glomerular filtration rate (GFR). The subjects 
collected a 24-hour urine specimen for determination 
of creatinine and volume immediately before each study 
in the Clinical Research Center. Blood for serum cre- 
atinine was sampled concomitantly with the first blood 
sample for PAH. At this time point, blood was also 
drawn on EGTA and glutathione for the analysis of 
plasma catecholamines. This blood sample was kept on 
melting ice until separation of plasma shortly; plasma 
was frozen and catecholamines analyzed with the ra- 
dioenzymatic method of Peuler and Johnson.' 
Statistical analysis. Data are given as mean val- 
ues -± SE. Blood pressure and vascular resistance were 
postulated to decrease in subjects receiving quinapril 
compared with placebo; therefore differences in these 
variables were tested by one-tailed tests; other differ- 
ences were tested by two-tailed parametric tests for 
single or repeated measurements. Correlation coeffi- 
cients (r) were calculated by use of the least-squares 
method. A p value less than 0.05 was considered to be 
the limit for statistical significance. 
RESULTS 
All the patients entered into the study completed the 
trial without notable side effects or adverse reaction. 
The data were tested for an order of treatment effect. 
Because this could not be found, further analyses were 
done by comparing the quinapril with the placebo pe- 
riod, regardless of the order in which they were given. 
Blood pressure. Systolic, diastolic, and mean blood 
pressure were all highly significantly lower on quinapril 
compared with placebo (p < 0.001, ANOVA). As 
shown by Table I, blood pressure was significantly 
lower in subjects receiving quinapril compared with 
placebo at all time points during the 4-hour period in 
the Clinical Research Center. Systolic and diastolic 
blood pressure differences between the two treatments 
before and 3 hours after the medication was given were 
16.4 -± 4.2/9.5 -± 2.6 and 14.0 -± 3.8/10.8 -± 2.3 
mm Hg, respectively. 
Six of the subjects responded with an average de- 
crease in mean blood pressure of more than 10 mm Hg, 
and two subjects responded with an average decrease 
in mean blood pressure between 5 and 10 mm Hg. After 
4 weeks of twice-daily quinapril therapy, further re- 
ductions in blood pressure were not observed during 
the 4-hour interval after quinapril dosing. 
Heart rate and plasma catechokimines. Heart rate 
did not show any significant difference between the two 
treatments (Table I). Plasma norepinephrine drawn 2.5 
hours after dose administration averaged 220 It 25 ver- 
sus 202 -±- 16 ng/L for subjects receiving quinapril and 
placebo, respectively (not significant), and plasma epi- 
nephrine was 45 -±- 5 versus 47 -± 10 ng /L (not sig- 
nificant). 
Forearm blood flow and forearm vascular resis- 
tance. Repeated measurement analysis of variance 
(ANOVA) did not reveal any statistically significant dif- 
ference for FBF or FVR (Table I) during placebo and 
quinapril treatments. 
Cardiac index and total peripheral resistance index. 
Cardiac function did not change significantly in subjects 
receiving quinapril treatment compared with placebo 
(Table II). Cardiac index averaged 2.51 ± 0.09 versus 
2.48 ± 0.09 L/ min/m2 body surface area 3 hours after 
dose administration on the two treatments, respectively 
(Fig. 1). As also shown in Fig. 1, TPRI was lower 
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A TPRI (Arbitrary Units) 
Fig. 2. Correlation between the differences in total peripheral 
resistance index (TPRI) and the differences in mean blood 
pressure (MBP) between treatment with quinapril versus pla- 
cebo (r = 0.72, p <0.05). 
tively (not significant). RBF was therefore statistically 
unchanged in subjects receiving quinapril (907 ± 36 
ml/ min) compared with placebo (896 ± 28 ml/ min). 
The filtration fraction was also unchanged. RVR, how- 
ever, was significantly (p < 0.05) lower in subjects 
receiving quinapril (12.2 ± 0.8 arbitrary units) com- 
pared with placebo (13.6 -± 0.6 arbitrary units), as 
shown in Fig. 3. The differences in RVR between the 
two treatments correlated with the differences in MAP 
between the two treatments (r = 0.63,p = 0.05). The 
change in RVR produced by quinapril was similar to 
the change in TPRI, and changes in the two resistance 
measurements were almost significantly correlated 
(r = 0.60, p < 0.07). 
DISCUSSION 
The present study showed that treatment of hyper- 
tensive subjects with quinapril, a novel nonsulfhydryl- 
ACE inhibitor, effectively lowers blood pressure at 
doses that do not cause notable side effects. The de- 
crease in blood pressure in subjects receiving long-term 
quinapril therapy occurred without an increase in 
plasma catecholamines, reflex tachycardia, or cardiac 
output, and the decrease in blood pressure was asso- 
ciated with decreased total peripheral resistance. Renal 
blood flow and glomerular filtration rate were pre- 
served, whereas renal vascular resistance showed a 
moderate decrease in patients receiving quinapril. Fore- 
arm blood flow and vascular resistance were unchanged 
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Fig. 1. Effects of quinapril on mean blood pressure (MBP), 
cardiac index (CI), and total peripheral resistance index 
(TPRI). Results are mean values + SE (n = 10). **Signif- 
icantly different from placebo at p < 0.01; ***significantly 
different from placebo at p < 0.001. 
for quinapril (43.4 ± 2.0 arbitrary units) compared 
with placebo (48.8 ± 1.8 arbitrary units, p < 0.01). 
Although the small decrease in LVM in subjects re- 
ceiving quinapril was not significant, wall stress was 
significantly decreased during quinapril treatment 
(Table II). 
The differences in TPRI between the two treatments 
correlated significantly with the differences in MAP 
between the two treatments (Fig. 2). 
Glomerular filtration rate and renal hemodynam- 
ics. GFR estimated by endogenous creatinine clearance 
remained statistically unchanged on quinapril compared 
with placebo (126 -± 9 versus 127 -± 10 ml/ min per 
1.73 m2 body surface area, respectively). 
PAH clearance averaged 521 -± 21 versus 519 -± 21 
ml/min and hematocrit 42.6 ± 1.2 versus 42.1 -± 1.1 
for subjects receiving quinapril and placebo, respec- 
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Fig. 3. Effects of quinapril on renal blood flow (RBF), renal 
vascular resistance (RVR), and glomerular filtration rate 
(GFR). Results are mean values + SE (n = 10). *Signifi- 
cantly different from placebo at p < 0.05. 
in patients receiving quinapril compared with placebo. 
Thus quinapril administered chronically lowers blood 
pressure by the same mechanism as other ACE inhib- 
itors; that is, it induces a decrease in total and re- 
nal vascular resistance without changing cardiac out- 
put, 12-l4,2628 The changes induced by quinapril are at 
variance with the reduced cardiac output and unchanged 
total peripheral resistance observed on B-adrenergic 
blockade.' /3-Blockade may worsen' the already de- 
pressed cardiac function' in hypertension. As opposed 
to 13-blockade, vasodilation with, for example, an ACE 
inhibitor may reverse the established vascular changes 
in hypertension and may be preferable for the long-term 
treatment of hypertension. 
The degree of counteracting reflex tachycardia and 
increase in cardiac output varies widely with vasodilator 
therapy of hypertension."' Even with a substantial de- 
crease in blood pressure in patients receiving quinapril, 
heart rate, cardiac output and plasma catecholamines 
remained virtually unchanged. The same observation 
has been made for captopril12,13,26-29 and enalapril14,30 
and lisinopril," and it appears to be a class effect of 
ACE inhibition. It has been shown that with capto- 
pri1,31'32 enalapril,"'" and lisinopri1,34 the absence of 
reflex tachycardia with blood pressure reduction may 
be related to increased parasympathetic tone. It is likely 
that the absence of tachycardia with quinapril has a 
similar mechanism. 
The reduction in systemic vascular resistance asso- 
ciated with chronic ACE inhibition appears to be un- 
evenly distributed through the circulation. Lisinopril did 
not change the splanchnic vascular resistance," and we 
did not detect a significant decrease in forearm vascular 
resistance in subjects receiving quinapril. However, 
captopril , 27'28 '36'37 lisinopril" and, in the present study, 
quinapril, reduced renal vascular resistance. This may 
be explained by the particularly pronounced vasocon- 
stricting action of angiotensin II in the renal circula- 
tion,3839 especially in patients with essential hyper- 
tension.' 
Long-term treatment of essential hypertension with 
captopril or enalapril has been associated with no 
change"'" or with a relatively small increase28'35'37 in 
renal blood flow and unchanged glomerular filtration 
rate. 28,35-37 ,41,42 An increase in renal blood flow may pos- 
sibly be related to withdrawal of the effect of angio- 
tensin, which is more potent in constricting the efferent 
than the afferent glomerular arteriole." However, a de- 
crease in filtration fraction may also indicate a redis- 
tribution of renal blood flow to more superficial neph- 
rons known to have a low filtration fractioe" or may 
relate to reduction in glomerular capillary hydraulic 
pressure.' In the present study, the decrease in blood 
pressure and renal vascular resistance was not accom- 
panied by a change in renal plasma flow, glomerular 
filtration rate or filtration fraction. Presumably, the fail- 
ure of renal blood flow to increase was attributable to 
reduction in perfusion pressure. Thus the antihyperten- 
sive effect of quinapril is not associated with compro- 
mise in autoregulation of renal hemodynamics. This 
conclusion is in agreement with studies in laboratory 
animals ,47 in which angiotensin II was not required for 
renal autoregulation. 
The infusion rate of PAH used in the present study 
achieved a plasma PAH concentration in the middle of 
the range in which tubular secretion dominates excre- 
tion.' At this level, PAH clearance is independent of 
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plasma concentration and represents about 90% of renal 
plasma flow." Therefore, use of PAH clearance may 
slightly underestimate true renal plasma flow. However, 
there is no reason to believe that quinapril per se influ- 
enced the renal extraction of PAH. 
We found left ventricular peak systolic wall stress in 
the same range as reported by others." Although we 
demonstrated a significant reduction in wall stress, 
which should promote regression of left ventricular hy- 
pertrophy, we did not find a significant reduction in 
LVM. It has been claimed that other ACE inhibitors 
decrease left ventricular mass.' However, a 4-week 
treatment period may be too short to detect regression 
of structural changes, and longer studies will be re- 
quired to determine whether the trend toward lower 
LVM that we observed during quinapril therapy is in- 
dicative of regression. 
After patients received 4 weeks of twice-daily qui- 
napril therapy, further reductions in blood pressure were 
not observed during the 4-hour interval after quinapril 
dosing. This finding is interesting inasmuch as the 
plasma half-life of quinaprilat is approximately 2 hours 
and quinaprilat plasma concentrations are quite low 12 
hours after a single 20 mg quinapril dose. These results 
suggest that stable blood pressure reduction can be 
achieved in patients with hypertension on chronic qui- 
napril therapy, but the antihypertensive action of qui- 
napril does not correlate well with quinaprilat phar- 
macokinetic parameters and may be more closely re- 
lated to prolonged ACE inhibition or distant effect on 
tissue angiotensin II concentration. 
In conclusion, we found that the antihypertensive 
effect of long-term quinapril therapy in patients with 
hypertension was associated with reduced total periph- 
eral resistance and unchanged cardiac output. No reflex 
tachycardia or increase in plasma catecholamines was 
seen. Quinapril reduced renal vascular resistance but 
preserved renal blood flow and glomerular filtration 
rate. Forearm blood flow and resistance were un- 
changed. 
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